US Bancorp
BBIO icon

US Bancorp’s BridgeBio Pharma BBIO Stock Holding History

US Bancorp’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Sell
7,459
-3,624
-33% -$254K ﹤0.01% 1509
2026
Q1 		$823K Buy
11,083
+2,162
+24% +$157K ﹤0.01% 1246
2025
Q4 		$682K Buy
8,921
+1,580
+22% +$104K ﹤0.01% 1365
2025
Q3 		$381K Buy
7,341
+393
+6% +$19.2K ﹤0.01% 1662
2025
Q2 		$300K Buy
6,948
+47
+0.7% +$1.71K ﹤0.01% 1794
2025
Q1 		$239K Buy
6,901
+2,446
+55% +$82.5K ﹤0.01% 1892
2024
Q4 		$122K Sell
4,455
-5,462
-55% -$141K ﹤0.01% 2294
2024
Q3 		$252K Buy
9,917
+320
+3% +$8.4K ﹤0.01% 1911
2024
Q2 		$243K Buy
9,597
+328
+4% +$8.97K ﹤0.01% 1890
2024
Q1 		$287K Sell
9,269
-6,387
-41% -$217K ﹤0.01% 1822
2023
Q4 		$632K Sell
15,656
-5,080
-24% -$153K ﹤0.01% 1360
2023
Q3 		$547K Sell
20,736
-9,460
-31% -$268K ﹤0.01% 1326
2023
Q2 		$519K Sell
30,196
-805
-3% -$12.1K ﹤0.01% 1377
2023
Q1 		$514K Buy
31,001
+29,597
+2,108% +$345K ﹤0.01% 1392
2022
Q4 		$10.7K Sell
1,404
-557
-28% -$5.33K ﹤0.01% 3276
2022
Q3 		$19K Buy
1,961
+123
+7% +$1.28K ﹤0.01% 3031
2022
Q2 		$17K Buy
1,838
+1,098
+148% +$9.18K ﹤0.01% 3133
2022
Q1 		$8K Buy
740
+671
+972% +$6.89K ﹤0.01% 3441
2021
Q4 		$1K Hold
69
– – ﹤0.01% 3961
2021
Q3 		$3K Sell
69
-12
-15% -$643 ﹤0.01% 3761
2021
Q2 		$5K Buy
81
+43
+113% +$2.46K ﹤0.01% 3599
2021
Q1 		$2K Buy
+38
New +$2.49K ﹤0.01% 3680

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

US Bancorp's BBIO Position: Q2 2026 in Review

US Bancorp reduced its BridgeBio Pharma (BBIO) stake by 33% in Q2 2026, selling an estimated $254K and leaving 7,459 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

US Bancorp first reported a position in BBIO in Q1 2021 and has held it in 22 quarters since. The position peaked at $823K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • US Bancorp held 7,459 shares of BridgeBio Pharma worth $556K as of Q2 2026.
  • US Bancorp sold 3,624 BridgeBio Pharma shares in Q2 2026, an estimated $254K.
  • BridgeBio Pharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1509 holding.
  • US Bancorp first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 22 quarters since.
  • US Bancorp's BridgeBio Pharma position peaked at $823K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.